Denial,
I enjoyed your analysis.
PAR is a higher allocation for me in my portfolio. I can easily see it doing well in the long term.
In the short term it's fairly unpredictable as evidenced by the share price ...and as others say, often there can be only a very loose link between what the company is doing and what the share price is doing, specially in these early days and add to this the lack of revenue only adds to this speculative type investment.
There are risks as you have identified and probably even a few more that we haven't considered. I keep thinking back to the days of Afterpay for example where it went from $7 to $21 and then there was speculation that the ACCC and others (I think AUSTRAK) were looking into them...that brought the price right back down to $11....it's only after that it made it's steady climb to where we find it today ($140 plus)...you'd have to be brave and understand the longer term perspective to hold all through it...but this is what worked eventually.
Now I'm not saying we should be blind to everything and just hold on...we have to constantly research, constantly watch what competitors are doing and even check out our own PAR and re-evaluate and reassess it's prospects...
I agree with Pool_boy...pain is the big one, there is nothing that addresses this like we do....without many side effects, without longer term ramifications (subject to more trials and longitudinal studies)....it looks good...and to get:
- Efficacy
- Durability
- Functionality
- Pain relief
All delivered relatively safely....
DMOAD is certainly a super boost if we get this title but in my opinion (and PB's), the market is large enough to make this compelling in it's own right. The pent up demand indeed will be huge.
WHAT IF WE ARE WRONG?
Again, I am not discounting at all your good post on the risks...we all should be not only wary of them, but take them into consideration when building our position in PAR or any other company/investment. There are chances like any investment that one of these could eventuate, maybe to a small extent...who knows. I also know you and others are amply aware of the merits and prospects of what we have. I'm just saying (agreeing) it's prudent to consider these risks. I certainly have and despite me having a good exposure, it wouldn't be quite the death of me if one or more of those risks eventuated.
I'll keep posting more evidence of why I think this thing is good, unique and should be successful, but always remember...there are risks and nothing in life is a dead set guarantee...except as they say, Death and Taxes.
DYOR
- Forums
- ASX - By Stock
- PAR
- Blind spots
PAR
paradigm biopharmaceuticals limited..
Add to My Watchlist
2.44%
!
42.0¢

Blind spots, page-6
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
42.0¢ |
Change
0.010(2.44%) |
Mkt cap ! $166.9M |
Open | High | Low | Value | Volume |
40.0¢ | 42.0¢ | 40.0¢ | $168.2K | 411.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3500 | 41.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
42.0¢ | 50665 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3500 | 0.410 |
1 | 1235 | 0.405 |
5 | 66500 | 0.400 |
4 | 67519 | 0.395 |
5 | 56650 | 0.390 |
Price($) | Vol. | No. |
---|---|---|
0.420 | 50665 | 2 |
0.425 | 2860 | 1 |
0.430 | 28500 | 1 |
0.440 | 45000 | 2 |
0.445 | 1400 | 1 |
Last trade - 16.11pm 18/07/2025 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |